<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030025</url>
  </required_header>
  <id_info>
    <org_study_id>ABDL-TBP-1001</org_study_id>
    <nct_id>NCT05030025</nct_id>
  </id_info>
  <brief_title>Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)</brief_title>
  <official_title>Single-Dose Fasting and Fed Pilot BE Study in Healthy Males and Females Not of Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for this study is to evaluate and understand the variability of a generic&#xD;
      alternative of abacavir, dolutegravir and lamivudine dispersible tablets for PEPFAR&#xD;
      submission to aide in the development of pivotal studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to investigate the bioequivalence of Mylan's abacavir, dolutegravir and&#xD;
      lamivudine dispersible tablets, 60 mg/5 mg/30 mg to ViiV's Triumeq Dispersible Tablets (5 mg&#xD;
      GSK1349572 [dolutegravir]/ 60 mg abacavir/ 30 mg lamivudine) following administration of a&#xD;
      single, oral 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg) dose of Mylan's abacavir, dolutegravir&#xD;
      and lamivudine dispersible tablets or ViiV's Triumeq Dispersible Tablets administered under&#xD;
      fasting and fed conditions.&#xD;
&#xD;
      Adverse events will be monitored to ensure the safety and well-being of the healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, randomized, two-period, two-treatment, two-group, crossover study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluation of Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) 0-t</measure>
    <time_frame>2 weeks</time_frame>
    <description>Plasma concentration-time curve from zero to the time of the last measurable time point t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)0-∞</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abacavir, Dolutegravir and Lamivudine Dispersible Tablets,60mg/5 mg/30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triumeq Dispersible Tablets, 5 mg/60 mg/30 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60mg/5mg/30mg</intervention_name>
    <description>Bioavailability</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: Triumeq Dispersible Tablets (5mg GSK1349572 [dolutegravir]/60mg abacavir/30mg lamivudine) (ViiV)</intervention_name>
    <description>Bioavailability</description>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Subject candidates must fulfill all of the following inclusion&#xD;
        criteria to be eligible for participation in the study, unless otherwise specified:&#xD;
&#xD;
          -  18 to 55 years old.&#xD;
&#xD;
          -  Males and/or females not of child-bearing potential.&#xD;
&#xD;
          -  Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs)&#xD;
             for women and have a Body Mass Index (BMI) value less than or equal to 30.0 kg/m2 but&#xD;
             greater than or equal to 19.0 kg/m2.&#xD;
&#xD;
          -  Adequate venous access in both arms.&#xD;
&#xD;
          -  Only non-tobacco/non-nicotine subjects.&#xD;
&#xD;
          -  Able to understand and sign the written Informed Consent Form.&#xD;
&#xD;
          -  Willing to follow the protocol requirements and comply with protocol restrictions.&#xD;
&#xD;
          -  All subjects should be judged by the Principal Investigator or Medical Sub-&#xD;
             Investigator as normal and healthy during a pre-study medical evaluation performed&#xD;
             within 28 days of the initial dose of study medication.&#xD;
&#xD;
        Exclusion Criteria - Subject candidates must not be enrolled in the study if subject meet&#xD;
        any of the following criteria:&#xD;
&#xD;
          -  Institutionalized subjects.&#xD;
&#xD;
          -  Social Habits, Medications and Diseases will be evaluated.&#xD;
&#xD;
          -  Use of certain foods and processed candies, gums food/drinks that contain sugar&#xD;
             alcohols.&#xD;
&#xD;
          -  Liver function tests (ALT, AST and total bilirubin).&#xD;
&#xD;
          -  Subjects who are positive for the HLA-B*5701 allele.&#xD;
&#xD;
          -  Subjects having Modified Patient Health Questionnaire (PHQ)-12 questionnaire score &gt;&#xD;
             4.&#xD;
&#xD;
          -  Subject has a creatinine clearance &lt; 90 mL/min, as determined by the Cockroft-Gault&#xD;
             equation.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Principal Investigator or Medical Sub-&#xD;
             Investigator, would prevent the subject from safely participating in the study.&#xD;
&#xD;
          -  Intolerance to venipuncture.&#xD;
&#xD;
          -  Donation or loss of blood or plasma.&#xD;
&#xD;
          -  Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Principal Investigator or Medical Sub-Investigator, could contraindicate the subject's&#xD;
             participation in this study.&#xD;
&#xD;
          -  Allergy or hypersensitivity to abacavir, dolutegravir, lamivudine, other related&#xD;
             products, or any inactive ingredients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey Lawrence, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin R Larnerd</last_name>
    <phone>304-554-5844</phone>
    <phone_ext>5844</phone_ext>
    <email>erin.larnerd@viatris.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Zachwieja, CCRA</last_name>
    <phone>304-680-0256</phone>
    <email>laura.zachwieja@viatris.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Altasciences</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Logan</last_name>
      <phone>514-779-9300</phone>
      <email>mlogan@altasciences.com</email>
    </contact>
    <investigator>
      <last_name>Eric Sicard, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Triumeq</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

